Regeneron Pharmaceuticals ((REGN)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Regeneron Pharmaceuticals is conducting a Phase 3 clinical trial titled ‘A Phase 3, Open-Label, Randomized Study to Compare the Efficacy and Safety of Odronextamab (REGN1979), an Anti-CD20x Anti-CD3 Bispecific Antibody, Combined With Chemotherapy Versus Rituximab Combined With Chemotherapy in Previously Untreated Participants With Follicular Lymphoma (OLYMPIA-2)’. The study aims to evaluate the safety and effectiveness of odronextamab combined with chemotherapy compared to the current standard treatment, rituximab with chemotherapy, for patients with follicular lymphoma.
The intervention being tested is odronextamab, an experimental bispecific antibody designed to target specific proteins on cancer cells, combined with chemotherapy drugs such as cyclophosphamide, doxorubicin, vincristine, and prednisone. The goal is to determine if this combination is more effective than the standard rituximab and chemotherapy regimen.
The study is interventional, with participants randomly assigned to different treatment groups. It follows a parallel intervention model and is open-label, meaning both researchers and participants know which treatment is being administered. The primary purpose is treatment-focused, aiming to improve outcomes for follicular lymphoma patients.
The study began on November 14, 2023, with its primary completion and estimated overall completion dates not yet specified. The last update was submitted on July 15, 2025. These dates are crucial for tracking the study’s progress and anticipating results that could influence treatment standards.
This study could significantly impact Regeneron’s market position if odronextamab proves more effective than existing treatments. Positive results might boost investor confidence and stock performance, while also affecting competitors in the oncology sector. The ongoing recruitment and updates suggest active progress, with further details accessible on the ClinicalTrials portal.